Health Canada Approves OPDIVO® plus YERVOY® as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

First new systemic therapy in more than 15 years for cancer related to asbestos exposure

 Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of OPDIVO ® (nivolumab) 360 mg every three weeks or 3mgkg every two weeks plus YERVOY ® (ipilimumab) 1 mgkg every six weeks (injections for intravenous use) for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM. i This is the first and only dual immunotherapy treatment for the condition. Unlike traditional cancer therapies that target the tumour directly, immuno-oncology activates the body's own immune system to help recognize and attack cancer cells. ii

Bristol Myers Squibb logo (CNW Group/Bristol Myers Squibb)

"Malignant pleural mesothelioma is a devastating cancer commonly related to exposure to asbestos. When faced with a diagnosis, patients currently have very few treatment possibilities," said Dr. Quincy Chu , medical oncologist, Cross Cancer Institute, Edmonton . "This approval is particularly important because it is the first dual immunotherapy developed to treat this disease. That means we now have an entirely new therapeutic option, helping us better support Canadian patients diagnosed with mesothelioma."

Mesothelioma is a rare and aggressive form of cancer that is mainly caused by asbestos exposure. iii Mesothelioma most often affects the pleural lining (the lining surrounding the lungs). iv Currently in Canada , the overall 5-year survival rate for mesothelioma is 7%. v Malignant Pleural Mesothelioma (MPM) accounts for approximately 80%–85% of cases. vi

"Today's approval represents an important step in addressing the challenging needs of people diagnosed with this devastating, life threatening cancer most commonly found in the lining surrounding the lungs, said Eudice Goldberg , Chair, Board of Directors, Canadian Mesothelioma Foundation. "With a poor long-term survival rate, any new treatments are welcomed by the mesothelioma community."

The Health Canada approval was based on a pre-specified interim analysis from the Phase 3 CheckMate-743 trial in which OPDIVO ® +YERVOY ® demonstrated superior overall survival (OS) versus the platinum-based standard of care chemotherapy.[vii] The primary endpoint of the trial was OS in all randomized patients. i Additional efficacy outcome measures included progression-free survival (PFS), and objective response rate (ORR). i

"We are pleased and proud to have OPDIVO ® + YERVOY ® now approved for the treatment of patients diagnosed with the most common form of mesothelioma," said Al Reba , General Manager, BMS Canada. "At BMS, our commitment to patients is an everyday, all-the-time promise. We continue to pursue innovative therapies that can help improve both patients' survival and quality of life."

About CheckMate-743
CheckMate-743 (NCT02899299) is an open-label, multi-center, randomized Phase 3 trial evaluating OPDIVO ® plus YERVOY ® compared to chemotherapy (pemetrexed and cisplatin or carboplatin) in patients with histologically confirmed unresectable malignant pleural mesothelioma and no prior systemic therapy or palliative radiotherapy within 14 days of initiation of therapy. viii

Health Canada and Project Orbis Collaboration Aims to Provide Earlier Availability to Cancer Treatments ix
Project Orbis is an initiative of the United States Food and Drug Administration (FDA) Oncology Center of Excellence. This submission was part of the FDA's Project Orbis initiative, enabling concurrent review by the health authorities in the United States , Australia , Brazil , Switzerland and Canada .

About Bristol Myers Squibb Canada Co.
Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb Canada Co. employs more than 400 people across the country. For more information, please visit https://www.bms.com/ca/en .

About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

__________________________________

i Canadian Product Monograph. Revised May 28, 2021.
https://www.bms.com/assets/bms/ca/documents/productmonograph/OPDIVO_EN_PM.pdf

ii Canadian Cancer Society. Immunotherapy. https://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/immunotherapy/?region=on . Accessed Nov 4, 2020.

iii https://survivornet.ca/learn/health-concerns-for-cancer-patients/asbestos-mesothelioma-lung-cancer/mesothelioma/ Accessed Nov 4, 2020.

iv https://survivornet.ca/learn/health-concerns-for-cancer-patients/asbestos-mesothelioma-lung-cancer/mesothelioma/ Accessed Nov 4, 2020.

v Canadian Cancer Society Survival statistics for mesothelioma. https://www.cancer.ca/en/cancer-information/cancer-type/mesothelioma/prognosis-and-survival/survival-statistics/?region=on Accessed Nov 4, 2020.

vi Shavelle R et al. Lung Cancer Int. 2017; https://dx.doi.org/10.1155/2017/2782590

vii Clinical trial (n=302) (Hazard Ratio [HR]: 0.74 [95% Confidence Interval [CI]: 0.61 to 0.89]; P=0.002), with a median OS (mOS) of 18.1 months (95% CI: 16.8 to 21.5) versus 14.1 months (95% CI: 12.5 to 16.2), respectively.1 These results were observed after 22.1 months of minimum follow-up.3 At two years, 41% of patients treated with Opdivo + Yervoy were alive and 27% with chemotherapy.

viii https://clinicaltrials.gov/ct2/show/NCT02899299?term=CheckMate-743&cond=Mesothelioma&draw=2&rank=1 Accessed Nov 4, 2020.

ix U.S. Food and Drug Administration. Project Orbis. https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis . Accessed Nov 4, 2020.

SOURCE Bristol Myers Squibb

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/June2021/02/c6383.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology .

About the Study

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less

Latest Press Releases

Related News

×